CA2379370A1 - Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer - Google Patents

Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer Download PDF

Info

Publication number
CA2379370A1
CA2379370A1 CA002379370A CA2379370A CA2379370A1 CA 2379370 A1 CA2379370 A1 CA 2379370A1 CA 002379370 A CA002379370 A CA 002379370A CA 2379370 A CA2379370 A CA 2379370A CA 2379370 A1 CA2379370 A1 CA 2379370A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
formula
hydroxy
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002379370A
Other languages
English (en)
Inventor
Tim Fat Tam
Khashayar Karimian
Wanren Li
Yingsheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apotex Inc
Original Assignee
Apotex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apotex Inc filed Critical Apotex Inc
Priority to CA002379370A priority Critical patent/CA2379370A1/fr
Publication of CA2379370A1 publication Critical patent/CA2379370A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002379370A 2002-03-28 2002-03-28 Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer Abandoned CA2379370A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002379370A CA2379370A1 (fr) 2002-03-28 2002-03-28 Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA002379370A CA2379370A1 (fr) 2002-03-28 2002-03-28 Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer

Publications (1)

Publication Number Publication Date
CA2379370A1 true CA2379370A1 (fr) 2003-09-28

Family

ID=28796448

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002379370A Abandoned CA2379370A1 (fr) 2002-03-28 2002-03-28 Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer

Country Status (1)

Country Link
CA (1) CA2379370A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006053429A1 (fr) 2004-11-19 2006-05-26 Apotex Inc. Procédé pour la fabrication de 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide et de ses analogues apparentés
US7410985B2 (en) 2003-11-20 2008-08-12 Apotex Inc. Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
KR20110096574A (ko) * 2008-12-11 2011-08-30 글락소스미스클라인 엘엘씨 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
US8580967B2 (en) 2008-07-25 2013-11-12 Shionogi & Co., Ltd. Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8865907B2 (en) 2009-03-26 2014-10-21 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097624B2 (en) 2003-11-20 2012-01-17 Apotex Inc. Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
US7410985B2 (en) 2003-11-20 2008-08-12 Apotex Inc. Cycloalkyl derivatives of 3-hydroxy-4-pyridinones
US7893269B2 (en) 2004-11-19 2011-02-22 Apotex Inc Process for the manufacture of 3-hydroxy-N-alkyl-1-cycloalky1-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
WO2006053429A1 (fr) 2004-11-19 2006-05-26 Apotex Inc. Procédé pour la fabrication de 3-hydroxy-n-alkyl-1-cycloalkyl-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide et de ses analogues apparentés
US8981129B2 (en) 2008-07-25 2015-03-17 Shionogi & Co., Ltd. 2-(2-hydroxy-2-phenylethyl)-3-[(phenylmethyl)oxy]-4H-pyran-4-one of the formula P-3 and/or 2-[(E)-2-phenylethenyl]-3-[(phenylmethyl)oxy]-4H-Pyran-4-one of the formula P-4
US9133216B2 (en) 2008-07-25 2015-09-15 Shionogi & Co., Ltd. (3S,11aR)-6-[(phenylmethyl)oxy]-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-9 and/or (3S,11aR)-6-[(phenymethyl)oxy]-8-bromo-3-methyl-2,3,11,11a-tetrahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-5,7-dione of the formula P-10
US9707246B2 (en) 2008-07-25 2017-07-18 Shionogi & Co., Ltd. Substituted (3S,11AR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11A-hexahydro[1,3]oxazolo[3,2-A]pyrido[1,2-D]pyrazine-8-carboxamides as HIV agents
CN105198804A (zh) * 2008-07-25 2015-12-30 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
US9012650B2 (en) 2008-07-25 2015-04-21 Shionogi & Co., Ltd. Substituted (3S, 11aR)-N-[(2,4-difluorophenyl)methyl]-6-oxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides of formula (I) useful as HIV agents
US8580967B2 (en) 2008-07-25 2013-11-12 Shionogi & Co., Ltd. Methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2-carboxylate and processes for the preparation thereof
US8940912B2 (en) 2008-07-25 2015-01-27 Viiv Healthcare Company 4-oxo-3-[(phenylmethyl)oxy]-4H-pyran-2-carboxylic acid
US8765965B2 (en) 2008-07-25 2014-07-01 Shionogi & Co., Ltd. 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7
KR20110096574A (ko) * 2008-12-11 2011-08-30 글락소스미스클라인 엘엘씨 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
KR20160127179A (ko) * 2008-12-11 2016-11-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
TWI450890B (zh) * 2008-12-11 2014-09-01 Viiv Healthcare Co 用於製備胺甲醯吡啶酮ｈｉｖ整合酶抑制劑之方法及中間體
JP2012511574A (ja) * 2008-12-11 2012-05-24 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
KR101682058B1 (ko) 2008-12-11 2016-12-02 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
US8624023B2 (en) 2008-12-11 2014-01-07 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8669362B2 (en) 2008-12-11 2014-03-11 Shiongi & Co., Ltd. Processes and Intermediates for carbamoylpyridone HIV integrase inhibitors
US8552187B2 (en) 2008-12-11 2013-10-08 Shionogi & Co., Ltd. Processes and intermediates for carbamoylpyridone HIV integrase inhibitors
EP2376453A4 (fr) * 2008-12-11 2012-06-27 Glaxosmithkline Llc Procédés et intermédiaires pour inhibiteurs de la carbomoylpyridone intégrase du hiv
EP2376453A1 (fr) * 2008-12-11 2011-10-19 GlaxoSmithKline LLC Procédés et intermédiaires pour inhibiteurs de la carbomoylpyridone intégrase du hiv
KR101678563B1 (ko) * 2008-12-11 2016-11-22 비이브 헬쓰케어 컴퍼니 카르바모일피리돈 ｈｉｖ 인테그라제 억제제를 위한 제조방법 및 중간체
US9242986B2 (en) 2008-12-11 2016-01-26 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US8754214B2 (en) 2008-12-11 2014-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US9365587B2 (en) 2008-12-11 2016-06-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
US9260453B2 (en) 2009-03-26 2016-02-16 Shionogi & Co., Ltd. Method for producing pyrone and pyridone derivatives
US9505783B2 (en) 2009-03-26 2016-11-29 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US8865907B2 (en) 2009-03-26 2014-10-21 Shionogi & Co., Ltd. Method of producing pyrone and pyridone derivatives
US9120817B2 (en) 2010-03-23 2015-09-01 Viiv Healthcare Company Process for preparing (4R,12aS)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′ ,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid
US8889877B2 (en) 2010-03-23 2014-11-18 Viiv Healthcare Company Processes for preparing pyridinone carboxylic acid aldehydes
US9643981B2 (en) 2010-03-23 2017-05-09 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-methoxy-4-methyl-6,8-dioxo-3,4,6,8,12,12A-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US9938296B2 (en) 2010-03-23 2018-04-10 Viiv Healthcare Company Process for preparing (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide
US10174051B2 (en) 2010-03-23 2019-01-08 Viiv Healthcare Company Substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US10233196B2 (en) 2010-03-23 2019-03-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives
US10647728B2 (en) 2010-03-23 2020-05-12 Viiv Healthcare Company Process for preparing (3S,11aR)-6-methoxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxylic acid
US10654871B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing (3S,11aR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
US10654870B2 (en) 2010-03-23 2020-05-19 Viiv Healthcare Company Process for preparing substituted pyridinones as intermediates in the preparation of polycyclic carbamoylpyridone derivatives

Similar Documents

Publication Publication Date Title
SU1181540A3 (ru) Способ получени сульфамоилзамещенного производного фенэтиламина и его кислотной соли
SU820659A3 (ru) Способ получени производных 4-амино- 5-АлКилСульфОНилОАНизАМидОВ, иХ СОлЕй,ОКиСЕй, лЕВО- и пРАВОВРАщАющиХизОМЕРОВ /иХ ВАРиАНТы/
US5554789A (en) Arylpropionic derivative, a process for the preparation and the use thereof as an analgesic agent
RU2544856C2 (ru) НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
US6573252B1 (en) Medicine nitrate salts
US4413141A (en) 2-(Difluoromethyl)-2,5-diaminopentanoic acid
JP2004359676A (ja) 置換チアゾリジンジオン誘導体
NO791597L (no) Imidazolderivater, samt fremgangsmaate til deres fremstilling
US6355269B1 (en) Oral compositions of levosimendan
EP0579681B1 (fr) Monohydrate d'hydrochlorure de tiagabine cristalline, sa preparation et son utilisation
KR101710740B1 (ko) 2-［［［2-［(히드록시아세틸)아미노］-4-피리디닐］메틸］티오］-ｎ-［4-(트리플루오로메톡시)페닐］-3-피리딘카르복사미드의 벤젠술폰산염, 이의 결정, 이의 결정 다형 및 이들의 제조 방법
JPS6229566A (ja) 新規グアニジノメチル安息香酸誘導体
GB2158440A (en) 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine derivatives
CA2379370A1 (fr) Derives d'acide carboxylique et de 3-hydroxy-4-oxo-1,4-dihydropyridine utilises comme chelateurs du fer
AU726239B2 (en) 2-phenoxyaniline derivatives
US4134991A (en) Derivatives of 2-(3-phenyl-2-aminopropionyloxy)-acetic acid
EP0591027A1 (fr) Dérivés de pipéridine, leur préparation et leur application en thérapeutique
EP0193965B1 (fr) Dérivés d'acide guanidinométhylcyclohexane-carboxylique, préparation et compositions pharmaceutiques
CA2105683C (fr) Acides n-¬(4,5-dihydroxy-et 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl)carbonyl|amines utiles pour les therapies d'affectations osteoarticulaires
FR2610932A1 (fr) Nouvel acide piperazinecarboxylique, sa preparation et son utilisation comme medicament
US4166128A (en) Substituted phenylglycolic acid and its pharmaceutically acceptable esters and salts, and processes for preparing the same
JPH03120271A (ja) 抗虚血活性を有するフェニルアルキルアミン誘導体
CA1162544A (fr) Derives de naphthyridine
JPS6312064B2 (fr)
JP2984403B2 (ja) イソキノロン誘導体

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20050329